QuidelOrtho (QDEL) is weighing the sale of its point-of-care testing business behind rapid COVID-19 antigen tests for about $1.5 billion, the Financial Times reported Saturday, citing people familiar with a matter.
The company is evaluating bids from private equity companies including Advent International, while other potential suitors like SK Capital Partners and Archimed have also expressed interest, sources told the media outlet.
QuidelOrtho did not immediately respond to a request for comment from.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: $18.58, Change: $+4.79, Percent Change: +34.74%